317 related articles for article (PubMed ID: 27158757)
21. PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes.
Bolze PA; Patrier S; Massardier J; Hajri T; Abbas F; Schott AM; Allias F; Devouassoux-Shisheboran M; Freyer G; Golfier F; You B
Int J Gynecol Cancer; 2017 Mar; 27(3):554-561. PubMed ID: 28060141
[TBL] [Abstract][Full Text] [Related]
22. A novel histological examination with dynamic three-dimensional reconstruction from multiple immunohistochemically stained sections of a PD-L1-positive colon cancer.
Korehisa S; Ikeda T; Okano S; Saeki H; Oki E; Oda Y; Hashizume M; Maehara Y
Histopathology; 2018 Mar; 72(4):697-703. PubMed ID: 28940664
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component.
Tanigawa M; Naito Y; Akiba J; Kawahara A; Okabe Y; Ishida Y; Ishikawa H; Hisaka T; Fujita F; Yasunaga M; Shigaki T; Sudo T; Mihara Y; Nakayama M; Kondo R; Kusano H; Shimamatsu K; Okuda K; Akagi Y; Yano H
Pathol Res Pract; 2018 Dec; 214(12):2069-2074. PubMed ID: 30477643
[TBL] [Abstract][Full Text] [Related]
24. Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition.
Kwon MJ; Rho YS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Kim ES; Park B; Hong M; Min KW
Hum Pathol; 2018 Oct; 80():28-39. PubMed ID: 29634978
[TBL] [Abstract][Full Text] [Related]
25. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
26. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
27. Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
Hacking S; Chavarria H; Jin C; Perry A; Nasim M
Pathol Res Pract; 2020 Apr; 216(4):152847. PubMed ID: 32085927
[TBL] [Abstract][Full Text] [Related]
28. Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling.
Kintsler S; Cassataro MA; Drosch M; Holenya P; Knuechel R; Braunschweig T
Ann Diagn Pathol; 2019 Aug; 41():24-37. PubMed ID: 31132649
[TBL] [Abstract][Full Text] [Related]
29. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
[TBL] [Abstract][Full Text] [Related]
30. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
Ng Kee Kwong F; Laggner U; McKinney O; Croud J; Rice A; Nicholson AG
Histopathology; 2018 May; 72(6):1024-1032. PubMed ID: 29323731
[TBL] [Abstract][Full Text] [Related]
31. The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells.
Parra ER; Villalobos P; Rodriguez-Canales J
Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):287-294. PubMed ID: 29135534
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
Pinto A; Mackrides N; Nadji M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
[TBL] [Abstract][Full Text] [Related]
33. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
[TBL] [Abstract][Full Text] [Related]
35. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
Calderaro J; Rousseau B; Amaddeo G; Mercey M; Charpy C; Costentin C; Luciani A; Zafrani ES; Laurent A; Azoulay D; Lafdil F; Pawlotsky JM
Hepatology; 2016 Dec; 64(6):2038-2046. PubMed ID: 27359084
[TBL] [Abstract][Full Text] [Related]
36. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
[TBL] [Abstract][Full Text] [Related]
37. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
[TBL] [Abstract][Full Text] [Related]
38. In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.
Bai Y; Guo T; Huang X; Wu Q; Niu D; Ji X; Feng Q; Li Z; Kakudo K
Virchows Arch; 2018 May; 472(5):779-787. PubMed ID: 29651624
[TBL] [Abstract][Full Text] [Related]
39. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
[TBL] [Abstract][Full Text] [Related]
40. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
